Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of talquetamab combinations versus daratumumab + pomalidomide + dexamethasone in relapsed or refractory multiple myeloma
2021-000202-22Phase 3Active
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of talquetamab, daratumumab, pomalidomide and dexamethasone in multiple myeloma (MM) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Progression-free survival. Started Jun 2022; status: active.
02
Drugs
talquetamabdaratumumabpomalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2021-000202-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000202-22.